<DOC>
	<DOCNO>NCT02248571</DOCNO>
	<brief_summary>This clinical trial crossover design determine patient ' preference capecitabine combination bevacizumab everolimus combination exemestane advance breast cancer patient evaluate , combination associate well quality life . To identify patient ' preference either therapy trial , patient without disease progression reason early discontinuation ask treatment preference treatment satisfaction . To correlate patient ' preference patient report outcomes ( PROs ) , quality life ( QoL ) assess baseline throughout study , use dedicated questionnaire . With similarly active treatment option , utmost importance identify treatment least negative impact patient ' quality life .</brief_summary>
	<brief_title>Patient Preference Everolimus Combination With Exemestane Capecitabine Combination With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Written informed consent must obtain prior study specific procedure . 1 . Adult woman ( ≥ 18 year age ) 2. . Postmenopausal status The investigator must confirm postmenopausal status . Postmenopausal status define either : Age ≥ 55 year one year amenorrhea Age &lt; 55 year one year amenorrhea postmenopausal level follicle stimulate hormone ( FSH ) Luteinizing hormone ( LH ) per local institutional standard Prior hysterectomy postmenopausal level FSH LH per local institutional standard Surgical menopause bilateral oophorectomy For woman therapyinduced amenorrhea , oophorectomy serial measurement FSH / estradiol need ensure postmenopausal status . Note : Ovarian radiation treatment luteinizing hormonereleasing hormone ( LHRH ) agonist ( goserelin acetate leuprolide acetate ) permit induction ovarian suppression . 3 . Pathologically confirmed HER2/neunegative , ER/PR positive inoperable metastatic adenocarcinoma breast 4 . Indication systemic palliative target therapy / first line chemotherapy failure least one nonsteroidal aromatase inhibitor therapy time disease course ( restriction regard number previous endocrine line ) 5 . No indication chemotherapeutic treatment include Taxanes Anthracyclines 6 . Measurable nonmeasurable disease per RECIST 1.1 7 . Adequate bone marrow , liver renal function ( accord current SmPCs treatment regimen ) 8 . ECOG performance status 02 9 . Fluent German ( spoken write ) language 1 . Prior palliative cytotoxic chemotherapy 2 . Prior exposure mTORInhibitors ( prior treatment exemestane allow ) 3 . Concomitant antihormonal therapy , study medication 4 . Symptomatic visceral metastasis ( deem investigator ) 5 . Uncontrolled CNS metastases 6 . Unstable skeletal metastasis 7 . Medically uncontrolled cardiovascular disease ( e.g . uncontrolled hypertension ) 8 . Medically uncontrolled diabetes mellitus 9 . Severe hepatic impairment ( ChildPugh C ) 10 . Inadequate organ function specify : Hemoglobin &lt; 9.0 g/dl Absolute neutrophil count ( ANC ) &lt; 1,5 x109/L Platelets &lt; 100 x109/L Creatinine clearance &lt; 30ml/min [ Cockcroft Gault ] 11 . Known HIV infection chronic hepatitis B C history hepatitis B C 12 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency 13 . Any contraindication study drug use excipients accord current SmPCs 14 . Concomitant use immunosuppressive agent chronic use systemic corticosteroid 15 . Use concomitant medication know interfere study drug 16 . Use concomitant medication know interfere study result ( e.g . hormonal therapy ) whole study duration 17 . Premenopausal patient 18 . Pregnant breast feeding patient 19 . Participation additional parallel interventional drug device study within four week start study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>inoperable</keyword>
	<keyword>metastatic</keyword>
	<keyword>HER2/neu-negative</keyword>
	<keyword>hormone receptor positive</keyword>
	<keyword>HR+</keyword>
	<keyword>female</keyword>
	<keyword>postmenopausal</keyword>
</DOC>